Last updated on May 28, 2021 at 13:26
Hodgkin lymphoma (HL) is a distinctive group of lymphoid neoplasms that are characterized by the presence of a special cell type called Reed-Sternberg cell (RS cells) which you can see the details of in the slide section. These cells originate from mature germinal centre B-cells. RS cells express CD30 and CD15.
HL is also characterised by the fact that the tumour consists of mostly inflammatory, responsive cells, and just a few cancerous cells. Actually, for this reason, HL has sometimes been called Hodgkin disease rather than lymphoma.
Unlike most non-Hodgkin lymphomas, Hodgkin lymphomas arise in a single lymph node and typically spreads to other lymph nodes in that region. For example, it is frequent that only the cervical lymph nodes are affected, or only the mediastinal lymph nodes, but rarely more regions at the same time.
There are five subtypes of HL, four of which are considered “classic Hodgkin lymphoma”:
- Classic Hodgkin lymphoma (95% of cases)
- Nodular sclerosis HL – most frequent subtype
- Mixed cellularity HL
- Lymphocyte rich HL
- Lymphocyte depletion HL – least frequent subtype
- Nodular lymphocyte predominant HL (5% of cases)
Hodgkin lymphoma is associated with EBV infection in many (but not all) cases, immunodeficiency and autoimmune diseases.
During the normal immune response will germinal centre B cell undergo somatic hypermutation (= affinity maturation) to develop more specific antibodies against a pathogen. In this process many of these B-cells fail to mutate their immunoglobulin heavy chain gene correctly and therefore die by apoptosis. The pathogenesis of Hodgkin lymphoma may involve a germinal centre B cell that fails to mutate its heavy chain gene and therefore should die of apoptosis, but something stops the apoptosis. EBV proteins may be the cause of this anti-apoptotic activity.
Classical Hodgkin lymphoma
Classical Hodgkin lymphoma (cHL) occurs in two different age peaks: around 15-30 years and above 55. Males are slightly more likely to get this diagnosis. cHL was the first curable lymphoma, and now 80-90% of cases are cured.
It frequently presents with painless cervical, axillary or mediastinal lymphadenomegaly. “B symptoms” are rare but may occur. Extranodal involvement is uncommon.
Most subtypes of cHL have good prognosis, except for the lymphocyte depletion type, which luckily is the rarest type. The 5-year survival rate is close to 100% for stage I and II, and around 50% for stage IV Hodgkin lymphoma.
Nodular sclerosis HL is the most frequent subtype, accounting for 50-70% of all cases of cHL. It most frequently affects mediastinal lymph nodes of patients in the 15-35 year range.
Nodular lymphocyte predominant Hodgkin lymphoma
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) accounts for only 5% of Hodgkin lymphomas. The cell type in this case is a variant Reed-Sternberg cell that is called L&H cell or popcorn cell. This cell expresses CD20 but not CD30 or CD15.
NLPHL usually presents with painless cervical or axillary lymphadenomegaly.
NLPHL usually affects children or adults between 30-40 years. It tends to recur but generally has a very good prognosis. 50% of NLPHL involves a translocation of the BCL6 gene.
Hodgkin lymphoma vs non-Hodgkin lymphoma
The reason the lymphoid neoplasms are classified this way is because these two types have different characteristics. They are summed up in the table below:
|Hodgkin lymphoma||Non-Hodgkin lymphoma|
|Often localized to a single lymph node region, cervical, axillary or mediastinal||Often localized to multiple lymph node regions|
|Extranodal involvement uncommon||Extranodal involvement common|
|Originate from B-cells||Originate from B, T or NK cells|
|Mostly affects adolescents and young adults patients||Mostly affects older patients (>55)|
|Very good prognosis||Prognosis depends on subtype|
|Very few cancer cells surrounded by inflammatory cells||Only cancer cells|
|Less common||More common|
Main symptom is painless lymphadenomegaly and B symptoms
29. High grade B cell lymphomas (BL, DLBCL). Plasma cell neoplasms
31. T/NK cell lymphomas